Clinical trial NCT05060276: Study to Assess an Anti-Trop2 Antibody Drug Conjugate in Relapsed or Refractory Solid Tumors
Official title: A Phase 1B, Dose-Escalation Study of the Safety and Preliminary Efficacy of an Anti-Trop2 Antibody Drug Conjugate (STI-3258) in Patients With Relapsed or Refractory Solid Tumors
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE1
Conditions: Relapsed Solid Neoplasm
Refractory Cancer
Solid Tumor, Adult
Keywords: relapsed or refractory solid tumors
Lead sponsor: Sorrento Therapeutics, Inc.
Sponsor class: INDUSTRY
First posted: 2021-09-29
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SEQUENTIAL
Intervention model description: To determine DLT and MTD, the design uses a 3+3 ascending dose cohort design evaluating up to five dose cohorts including: 8 mg/kg, 12 mg/kg, 16 mg/kg, 20 mg/kg, 24 mg/kg.
Primary purpose: TREATMENT

Brief summary: This is a phase 1b, open-label, dose-escalation study o STI-3258 administered intravenously in subjects with relapsed or refractory solid tumors.

Detailed description: This is a Phase 1b, open-label, dose-escalation study o STI-3258 administered intravenously in subjects with relapsed or refractory solid tumors including ovarian, breast, lung, esophageal, gastric, hepatocellular and urothelial cancers.

The study will determine any dose limiting toxicity (DLT), maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), assessing safety and preliminary efficacy using ascending dose cohorts and a conventional 3+3 study design.

Eligibility criteria: Inclusion Criteria:

* Histologically or cytologically confirmed advanced cancer that is relapsing or refractory to at least one prior treatment and not a candidate for other treatments or is intolerant to established treatments.
* At least one measurable disease per Response Evaluation Criteria in Solid Tumors v. 1.1 (RECIST 1.1).
* Eastern Cooperative Oncology Group Performance Status ≤ 2.
* Must have a life expectancy of ≥ 6 months.
* Must have adequate bone marrow, hepatic and renal function as assessed by specific laboratory tests.
* Must be recovered ≤ Grade 1 from acute toxicities from previous therapies, excluding alopecia and vitiligo.
* Has not had prior treatment within 2 weeks of screening with high dose corticosteroids.
* Be willing and able to comply with the study schedule and all study requirements.
* Willing to follow all contraception guidelines.

Exclusion Criteria:

* Previous treatment with any systemic therapy or investigational drug within 2 weeks of the first dose of study drug.
* Currently participating in any other interventional clinical study.
* Has a diagnosis of other malignancies if the malignancy has required therapy within the last 3 years or is not in complete remission.
* Has presence of bulky disease defined as any mass \> 7 cm in greatest dimension will trigger a discussion with the medical monitor.
* Has left ventricular ejection fraction (LVEF) \< 40%.
* New York Heart Association (NYHA) Class ≥ 3.
* Has prolonged QTcF interval on an electrocardiogram.
* Has spinal cord compression or clinically active brain metastases.
* Has a history of Sacituzumab govitecan treatment.
* History of anaphylactic reaction to irinotecan or ≥ Grade 3 toxicity to prior irinotecan treatment.
* Has active or prior COVID-19 infection, with symptoms presenting within 4 weeks of the first dose of study drug.
* Has an active bacterial, viral, or fungal infection.
* Is currently pregnant or breast feeding or planning on either during the study.
* Has chronic or moderate chronic obstructive pulmonary disease or other chronic respiratory conditions unless receiving treatment and stable for 3 months prior to screening.
* Has known HIV or acquired immunodeficiency syndrome-related illness, acute or history of chronic hepatitis B or C.
* Has any significant medical condition, abnormality, or psychiatric illness that would prevent study participation.

Primary outcomes:
measure: Incidence of adverse events by type, frequency, severity, and causality (safety)
timeFrame: Baseline through study completion at up to approximately 24 months
measure: Incidence of treatment-emergent adverse events by type, frequency, severity, and causality (safety)
timeFrame: Baseline through study completion at up to approximately 24 months
measure: Incidence of serious adverse events by type, frequency, severity, and causality (safety)
timeFrame: Baseline through study completion at up to approximately 24 months
measure: Incidence of Infusion-related adverse events by type, frequency, severity, and causality (safety)
timeFrame: Baseline through study completion at up to approximately 24 months
measure: Incidence of dose-limiting toxicities (safety)
timeFrame: Baseline through study completion at up to approximately 24 months
measure: Determine the MTD
timeFrame: Baseline through study completion at up to approximately 24 months
measure: Determine the RP2D
timeFrame: Baseline through study completion at up to approximately 24 months
Secondary outcomes:
measure: Assess preliminary efficacy of STI-3258
timeFrame: Baseline through study completion at up to approximately 24 months
measure: Assess the area under the curve (AUC) pharmacokinetic profile of STI-3258
timeFrame: Baseline through study completion at up to approximately 24 months
Other outcomes:
Locations:
Study officials:
affiliation: Sorrento Therapeutics, Inc.
name: Mike Royal, MD
role: STUDY_DIRECTOR
References: